New ASCO recommendations regarding ovarian toxicity

Published Catarina de Freitas on Mon, 10/23/2023 - 13:34

Monday Lunch Live

16th October 2023

A Research Statement from the American Society of Clinical Oncology (ASCO), released 2 October 2023 has outlined new recommendations for appropriate assessment of ovarian toxicity in cancer clinical trials.

Previously, there has been inadequate data regarding whether newer cancer treatments can cause treatment-related infertility and early-onset menopause, despite the importance of this information to young women.

This statement calls for ovarian toxicity monitoring to be standard in cancer clinical trials involving premenopausal patients and outlines the optimal way to do this – including ovarian function tests at trial outset and 12 to 24 months after women stop taking the trial drug. As a result, young women who enrol in clinical trials can be more comprehensively monitored to check if new treatments have any impact on their ovaries.

In this webinar, Dr Wanda Cui discusses the recommendations and what clinicians should be aware of.

 

Course Details

Ovary
Course type
Webinars
Duration
60 mins
Price
$0.00
Curriculum Area
Clinical Care
Speciality
Clinician
Monday Lunch Live
Gynae-oncology
Clinical care

This course is brought to you by

Alliance members